The natural history of progressive fibrosing interstitial lung diseases


Affiliations: 1Dept of Medicine, National Jewish Health, Denver, CO, USA. 2Dept of Medicine, Weill Cornell Medicine, New York, NY, USA. 3National Heart and Lung Institute, Imperial College, London, UK. 4Division of Pulmonary, Allergy and Critical Care Medicine, University of Alabama at Birmingham, Birmingham, AL, USA. 5Dept of Respiratory Medicine, MHH Hannover Medical School and Biomedical Research in Endstage and Obstructive Lung Disease [BREATHE], Deutsches Zentrum für Lungenforschung (DZL), Hannover, Germany. 6Boehringer Ingelheim Pharmaceuticals, Inc., Ridgefield, CT, USA. 7Boehringer Ingelheim Pharma GmbH & Co. KG, Biberach, Germany. 8Boehringer Ingelheim International GmbH, Ingelheim am Rhein, Germany. 9Dept of Sports Medicine, University of Tübingen, Tübingen, Germany. 10National Reference Centre for Rare Pulmonary Diseases, Louis Pradel Hospital, Hospices Civils de Lyon, UMR 754, Claude Bernard University Lyon 1, Lyon, France. 11National Institute for Health Research Respiratory Biomedical Research Unit, Royal Brompton and Harefield NHS Foundation Trust, London, UK.

Correspondence: Kevin K. Brown, Dept of Medicine, National Jewish Health, 1400 Jackson Street, Denver, CO 80206, USA. E-mail: brownk@njhealth.org

Analyses of data from the INBUILD and INPULSIS trials suggest that progressive fibrosing ILDs other than IPF have a clinical course similar to IPF, irrespective of underlying ILD diagnosis or the fibrotic pattern on HRCT http://bit.ly/3apG0Q5


This single-page version can be shared freely online.

ABSTRACT We used data from the INBUILD and INPULSIS trials to investigate the natural history of progressive fibrosing interstitial lung diseases (ILDs).

Subjects in the two INPULSIS trials had a clinical diagnosis of idiopathic pulmonary fibrosis (IPF) while subjects in the INBUILD trial had a progressive fibrosing ILD other than IPF and met protocol-defined criteria for ILD progression despite management. Using data from the placebo groups, we compared the rate of decline in forced vital capacity (FVC) (mL·year\(^{-1}\)) and mortality over 52 weeks in the INBUILD trial with pooled data from the INPULSIS trials.

The adjusted mean annual rate of decline in FVC in the INBUILD trial (n=331) was similar to that observed in the INPULSIS trials (n=423) (−192.9 mL·year\(^{-1}\) and −221.0 mL·year\(^{-1}\), respectively; nominal p-value=0.19). The proportion of subjects who had a relative decline in FVC >10% predicted at Week 52 was 48.9% in the INBUILD trial and 48.7% in the INPULSIS trials, and the proportion who died over 52 weeks was 5.1% in the INBUILD trial and 7.8% in the INPULSIS trials. A relative decline in FVC >10% predicted was associated with an increased risk of death in the INBUILD trial (hazard ratio 3.64) and the INPULSIS trials (hazard ratio 3.95).

These findings indicate that patients with fibrosing ILDs other than IPF, who are progressing despite management, have a subsequent clinical course similar to patients with untreated IPF, with a high risk of further ILD progression and early mortality.

Copyright ©ERS 2020. This version is distributed under the terms of the Creative Commons Attribution Non-Commercial Licence 4.0.